Q&A with the Academy of Nutrition and Dietetics on malnutrition's greatest challenges and opportunities
What if your doctor handed out grocery lists, not a grocery list of pills to take?
Pharma companies and providers in search of better solutions must look to the patient experience for answers.
A closer look at how fast change may happen, who could win (and lose), and how the next decade may unfold for incumbents and new market entrants.
2018 was a big year for industry news. Here's what might happen next in artificial intelligence, the 2020 presidential election, pharma, and more.
Some of our 2018 predictions on consolidation, pharma, and investment came true, while others were less predictable.
Physicians are best positioned to curtail the $265 billion wasted annually on unneeded care.
Seeing a return on investment in pharma marketing means understanding what happens to every dollar.
Oliver Wyman Actuarial Consulting analyzes what happens after manufacturer costs for brand drugs change hands.
Our new advice for the Blues, who are in a formative period as market trends create both sizable risk and sizable opportunity.
In light of breaking news, the pharma value chain is definitely ripe for disruption. Here's how health plans, employers, and drug companies can adjust to the new normal.
_145x171.jpg)
